Acorah Software Products - Accounts Production 16.3.350 false true false true No description of principal activity 18 May 2024 30 April 2025 30 April 2025 15727658 Dr Y Alawsi iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 15727658 2024-05-17 15727658 2025-04-30 15727658 2024-05-18 2025-04-30 15727658 frs-core:CurrentFinancialInstruments 2025-04-30 15727658 frs-bus:PrivateLimitedCompanyLtd 2024-05-18 2025-04-30 15727658 frs-bus:FilletedAccounts 2024-05-18 2025-04-30 15727658 frs-bus:Micro-entities 2024-05-18 2025-04-30 15727658 frs-bus:AuditExempt-NoAccountantsReport 2024-05-18 2025-04-30 15727658 frs-bus:Director1 2024-05-18 2025-04-30
Registered number: 15727658
Yara Medical Limited
Unaudited Financial Statements
For the Period 18 May 2024 to 30 April 2025
Balance Sheet
Registered number: 15727658
30 April 2025
£
Current assets 43,321
Creditors: Amounts Falling Due Within One Year (12,215 )
NET CURRENT ASSETS 31,106
TOTAL ASSETS LESS CURRENT LIABILITIES 31,106
Accruals and deferred income (816 )
NET ASSETS 30,290
CAPITAL AND RESERVES 30,290

Notes

1. General Information
Yara Medical Limited is a private company, limited by shares, incorporated in England & Wales, registered number 15727658 . The registered office is 19 Gadwall Way, Scunthorpe, South Humberside, DN16 3UU.
2. Average Number of Employees
Average number of employees, including directors, during the period was: 1
1
For the period ending 30 April 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The member has not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges her responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared in accordance with the micro-entity provisions and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
On behalf of the board
Dr Y Alawsi
Director
23rd June 2025